PUBLISHER: DelveInsight | PRODUCT CODE: 2082650
PUBLISHER: DelveInsight | PRODUCT CODE: 2082650
Esophageal Cancer - Epidemiology Forecast - 2036
Esophageal cancer Insights and Trends
- According to DelveInsight's estimates, the total incident cases of esophageal cancer in the 7MM were approximately 79,000 in 2025
- Across the EU4 and the UK, the UK captured the largest portion of the esophageal cancer market, accounting for roughly 36% of the total, with Germany holding the second-largest share. Among the seven major markets, Japan reported the highest number of newly diagnosed esophageal cancer cases at approximately 27,000 in 2025, followed by the United States.
- In 2025, age-specific data indicated that individuals aged 65 and above had the highest number of esophageal cancer cases in the United States, whereas those under 45 accounted for the fewest cases. Additionally, males represented 80% of cases, compared to 20% in females.
- As per Surveillance Epidemiology and End Results Program SEER (2022), there were 2.2% in the below 45 years age group, 35.4% cases in the 45-64 years age group, and 62.4% cases in the 65 years and above age group.
- Japan accounted for around 36% of the total diagnosed incident cases of esophageal cancer in the 7MM in 2025.
Esophageal cancer Epidemiology Forecast in the United States
- 2025 Incident Cases of Esophageal Cancer: ~21,400
- Esophageal Cancer Growth Rate (2026-2036): 1.8% CAGR
DelveInsight's 'Esophageal Cancer - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the esophageal cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Esophageal cancer Understanding and Diagnosis Algorithm
Esophageal cancer Overview
Esophageal cancer is a malignant tumor arising from the inner lining of the esophagus, the tube that connects the throat to the stomach. The two main histological subtypes are squamous cell carcinoma (ESCC), commonly associated with tobacco and alcohol use, and adenocarcinoma (EAC), which is more prevalent in developed regions and is strongly linked to chronic gastroesophageal reflux disease (GERD) and Barrett's esophagus. The disease is often aggressive, with a tendency for late diagnosis due to nonspecific early symptoms, leading to poor prognosis and reduced survival rates. The global burden of esophageal cancer is increasing, driven by lifestyle factors, dietary habits, obesity, and aging populations. Despite advances in treatment, the overall 5-year survival rate remains low, particularly in advanced or metastatic stages, highlighting the need for early detection and improved therapeutic strategies.
Esophageal cancer Diagnosis
Esophageal cancer is a malignant tumor arising from the inner lining of the esophagus and is primarily classified into two main subtypes: squamous cell carcinoma, commonly associated with tobacco and alcohol use, and adenocarcinoma, which is linked to chronic gastroesophageal reflux disease (GERD) and Barrett's esophagus. The disease is highly aggressive and often diagnosed at an advanced stage due to nonspecific early symptoms, resulting in poor prognosis and low survival rates. Diagnosis typically involves a combination of clinical evaluation and advanced diagnostic techniques, with upper gastrointestinal endoscopy serving as the gold standard for visualization and biopsy confirmation. Histopathological analysis helps determine tumor type and grade, while imaging modalities such as CT scans, endoscopic ultrasound, and PET scans are essential for staging and assessing disease spread. In addition, molecular and biomarker testing, including HER2 and PD-L1 expression, is increasingly used to guide targeted and immunotherapy-based treatment decisions, reflecting a shift toward more personalized management of esophageal cancer.
Esophageal cancer Epidemiology
Key Findings from Esophageal cancer Epidemiological Analysis and Forecast
- It has been observed that the incidence of non-squamous cell esophageal cancer is higher (~14,000) as compared to squamous cell esophageal cancer (~8000) in the United States.
- It is observed that esophageal cancer is found to be more incident in males (~17,000) as compared to females (~5,000) in the United States.
- Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2025.
- In 2025, among total-stage specific cases, distant esophageal cancer was the most incident followed by regional stage-specific esophageal cancer in Germany.
- In the United States, among all the age groups, >=65 years accounted for the highest number of esophageal cancer cases, i.e., around ~14,000, in 2025, followed by the age-group 45-65 years (~8,000).
Scope of the Report:
The report covers a segment of an executive summary, a descriptive overview of Esophageal cancer, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Esophageal cancer Patient Population Forecast
Report Key Strengths
- Epidemiology-based (epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of esophageal cancer? What will be the growth opportunities across the 7MM concerning the patient population with esophageal cancer?
- What is the historical and forecasted esophageal cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Esophageal Cancer
4. Epidemiology Forecast Methodology
5. Esophageal Cancer Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Esophageal Cancer Disease Background and Overview
- 6.1. Introduction
- 6.2. Symptom
- 6.3. Transmission and Risk Factors
- 6.4. Pathophysiology
- 6.5. Diagnosis and Screening
- 6.5.1. Diagnostic Algorithm
- 6.5.2. Diagnosis Guidelines
7. Esophageal Cancer Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Incident Cases of Esophageal Cancer in the 7MM
- 7.4. The United States
- 7.4.1. Total Diagnosed Incident Cases of Esophageal Cancer in the United States
- 7.4.2. Histology-specific Cases of Esophageal Cancer in the United States
- 7.4.3. Gender-specific Cases of Esophageal Cancer in the United States
- 7.4.4. Age-specific Cases of Esophageal Cancer in the United States
- 7.4.5. Mutation-specific Cases of Esophageal Cancer in the United States
- 7.4.6. Total Stage-specific Cases of Esophageal Cancer in the United States
- 7.4.7. Line wise Treated Cases of Esophageal Cancer in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK
- 7.5.2. Histology-specific Cases of Esophageal Cancer in EU4 and the UK
- 7.5.3. Gender-specific Cases of Esophageal Cancer in EU4 and the UK
- 7.5.4. Age-specific Cases of Esophageal Cancer in EU4 and the UK
- 7.5.5. Mutation-specific Cases of Esophageal Cancer in EU4 and the UK
- 7.5.6. Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK
- 7.5.7. Line wise Treated Cases of Esophageal Cancer in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Diagnosed Incident Cases of Esophageal Cancer in Japan
- 7.6.2. Histology-specific Cases of Esophageal Cancer in Japan
- 7.6.3. Gender-specific Cases of Esophageal Cancer in Japan
- 7.6.4. Age-specific Cases of Esophageal Cancer in Japan
- 7.6.5. Mutation-specific Cases of Esophageal Cancer in Japan
- 7.6.6. Total Stage-specific Cases of Esophageal Cancer in Japan
- 7.6.7. Line wise Treated Cases of Esophageal Cancer in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: Summary of Esophageal Cancer, Epidemiology (2022-2036)
- Table 2: Key Events
- Table 3: AJCC Staging of Esophageal Cancer
- Table 4: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2022-2036)
- Table 5: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2022-2036)
- Table 6: Age-specific Cases of Esophageal Cancer in the US (2022-2036)
- Table 7: Histology-specific Cases of Esophageal Cancer in the US (2022-2036)
- Table 8: Gender-specific Cases of Esophageal Cancer in the US (2022-2036)
- Table 9: Mutation-specific Cases of Esophageal Cancer in the US (2022-2036)
- Table 10: Stage-specific Cases of Esophageal Cancer in the US (2022-2036)
- Table 11: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 12: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 13: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 14: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 15: Mutation-specific cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 16: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Table 17: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2022-2036)
- Table 18: Age-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Table 19: Histology-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Table 20: Gender-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Table 21: Mutation-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Table 22: Stage-specific Cases of Esophageal Cancer in Japan (2022-2036)
List of Figures
- Figure 1: Understanding Gastroesophageal Reflux Induced Esophageal Tumorigenesis
- Figure 2: Predominant Types of Primary Esophageal Cancers
- Figure 3: Staging of Esophageal Cancer
- Figure 4: The Risk Factors Profiles for Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
- Figure 5: Esophageal Cancer Warning Signs
- Figure 6: Top Alterations in Esophageal Squamous Cell Carcinoma
- Figure 7: Esophageal Cancer (Upper Endoscopy)
- Figure 8: Algorithm for the Symptoms Suggestive of Esophageal Cancer
- Figure 9: Imaging Differential Diagnosis
- Figure 10: Esophagectomy
- Figure 11: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2022-2036)
- Figure 12: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2022-2036)
- Figure 13: Age-specific Cases of Esophageal Cancer in the US (2022-2036)
- Figure 14: Histology-specific Cases of Esophageal Cancer in the US (2022-2036)
- Figure 15: Gender-specific Cases of Esophageal Cancer in the US (2022-2036)
- Figure 16: Mutation-specific Cases of Esophageal Cancer in the US (2022-2036)
- Figure 17: Stage-specific Cases of Esophageal Cancer in the US (2022-2036)
- Figure 18: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 19: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 20: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 21: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 22: Mutation-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 23: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2022-2036)
- Figure 24: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 25: Age-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 26: Histology-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 27: Gender-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 28: Mutation-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 29: Stage-specific Cases of Esophageal Cancer in Japan (2022-2036)
- Figure 30: Health Technology Assessment
